Ocumetra launches products to help clinicians manage myopia
Click Here to Manage Email Alerts
Key takeaways:
- Ocumetra launched mEYE Guide and mEYE Gauge in January.
- The products are intended to help address barriers to myopia management.
NEW YORK — Ocumetra, an optometric data analytics company, announced the January launch of its myopia management products, mEYE Guide and mEYE Gauge, at Vision Expo East.
Co-founder and optometrist James Loughman, PhD, told Healio that Ocumetra has acquired epidemiologic and industry data “to support doctors who are thinking of doing this new way of myopia management.”
Ocumetra conducted research with doctors to identify the barriers to transitioning to this type of care and identified clinical, education, confidence and financial challenges, Loughman said. The first two products, launched in January in collaboration with CooperVision, are intended to help address these barriers.
The web-accessible platform, mEYE Guide, is a parent communication tool designed to increase uptake and retention of myopia management while maximizing chair time, according to a company press release.
“It provides tools for clinicians to have that first conversation with parents to convince parents about myopia management,” Loughman said. “The tools were designed to make it easier for the clinicians to engage. Guidelines are changing rapidly. This provides a single package with all the guidelines. It helps protect the doctor from potential legalities of not doing it properly.”
Parents can scan a QR pop-up to get their child’s myopia management report, which shows how they compare with other children by percentile.
“It can show parents the benefits — how much reduction in myopia can be expected in the immediate future as well as the lifetime benefits, and the risks with and without treatment,” he said.
The mEYE Guide accomplishes this by using refraction centile graphs, a vision simulator and treatment benefit infographics, according to the release.
It also provides myopia treatment options in the child’s area and information on additional measures, such as increasing time outdoors and optimizing near work, Loughman said.
Pending regulatory approval, the platform will also provide treatment monitoring tools to support evidence-based clinical decision-making so clinicians can individualize and optimize the approach for each child, the release said.
“Axial length has been recognized as critical in myopia management,” Loughman added, “and most clinicians don’t have biometers. They don’t know what the axial length measurement means.”
“The mEYE Gauge is a predictor to help estimate it with 95% confidence limits within ±0.5 mm,” Loughman said. “Biometry is a more accurate metric to measure progression and monitor change.”
The company said in the release: “Ocumetra’s strategic vision is to deliver a revolution in myopia management, to power the change from vision correction to comprehensive myopia care and to provide [eye care professionals] with solutions that support the long-term growth of their myopia management practice.”
Collapse
Healio Interviews
Click Here to Manage Email Alerts